Yusuke Kurita1, Noritoshi Kobayashi2, Motohiko Tokuhisa3, Ayumu Goto3, Kensuke Kubota4, Itaru Endo5, Atsushi Nakajima4, Yasushi Ichikawa3. 1. Department of Oncology, Yokohama City University School of Medicine, Yokohama, Japan; Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan. 2. Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan. Electronic address: norikoba@yokohama-cu.ac.jp. 3. Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan. 4. Department of Oncology, Yokohama City University School of Medicine, Yokohama, Japan. 5. Department Gastroenterological Surgery, Yokohama City University School of Medicine, Yokohama, Japan.
Abstract
BACKGROUND/ OBJECTIVES: FOLFIRINOX is the reliable treatments for pancreatic cancer, but it has a relatively high toxicity and the selection of suitable patients for this regimen remains challenge. On the other hand, sarcopenia is one of the important prognostic factors of pancreatic cancer. The aim of this study was to investigate the effect of sarcopenia on overall survival (OS) and time to treatment failure (TTF) in patients with pancreatic cancer who received FOLFIRINOX. METHODS: Clinical data of consecutive patients treated with FOLFIRINOX at our institution from 2011 to 2017 was retrospectively reviewed. Skeletal muscle index (SMI) and adipose tissue index (ATI) at the third lumbar spine level was calculated from computed tomography (CT) images. The association between clinical factors (SMI and ATI), and OS and TTF were determined using univariate and multivariate analyses. RESULTS: We assessed 82 patients. The median OS of sarcopenia and the non-sarcopenia patients were 11.3 and 17.0 months, respectively (hazard ratio [HR], 2.49; 95% confidence interval [CI], 1.43-4.32; p = 0.001). Median TTF was 3.0 and 6.1 months in the sarcopenia and the non-sarcopenia patients, respectively (HR, 1.67; 95% CI, 1.03-2.71; p = 0.032). Multivariate analyses revealed that sarcopenia (HR, 1.37; 95% CI, 1.01-1.87; p = 0.045) was an independent prognostic factor of OS. High ATI (p = 0.022) and sarcopenic obesity (p = 0.008) were significantly associated with hematologic toxicity. CONCLUSIONS: Sarcopenia is an independent indicator of poor prognosis in patients with pancreatic cancer who received FOLFIRINOX, while ATI and sarcopenic obesity predicted severe hematologic toxicity.
BACKGROUND/ OBJECTIVES:FOLFIRINOX is the reliable treatments for pancreatic cancer, but it has a relatively high toxicity and the selection of suitable patients for this regimen remains challenge. On the other hand, sarcopenia is one of the important prognostic factors of pancreatic cancer. The aim of this study was to investigate the effect of sarcopenia on overall survival (OS) and time to treatment failure (TTF) in patients with pancreatic cancer who received FOLFIRINOX. METHODS: Clinical data of consecutive patients treated with FOLFIRINOX at our institution from 2011 to 2017 was retrospectively reviewed. Skeletal muscle index (SMI) and adipose tissue index (ATI) at the third lumbar spine level was calculated from computed tomography (CT) images. The association between clinical factors (SMI and ATI), and OS and TTF were determined using univariate and multivariate analyses. RESULTS: We assessed 82 patients. The median OS of sarcopenia and the non-sarcopeniapatients were 11.3 and 17.0 months, respectively (hazard ratio [HR], 2.49; 95% confidence interval [CI], 1.43-4.32; p = 0.001). Median TTF was 3.0 and 6.1 months in the sarcopenia and the non-sarcopeniapatients, respectively (HR, 1.67; 95% CI, 1.03-2.71; p = 0.032). Multivariate analyses revealed that sarcopenia (HR, 1.37; 95% CI, 1.01-1.87; p = 0.045) was an independent prognostic factor of OS. High ATI (p = 0.022) and sarcopenic obesity (p = 0.008) were significantly associated with hematologic toxicity. CONCLUSIONS:Sarcopenia is an independent indicator of poor prognosis in patients with pancreatic cancer who received FOLFIRINOX, while ATI and sarcopenic obesity predicted severe hematologic toxicity.
Authors: Gabriel F P Aleixo; Shlomit S Shachar; Kirsten A Nyrop; Hyman B Muss; Claudio L Battaglini; Grant R Williams Journal: Oncologist Date: 2019-11-12
Authors: Ali N Gunesch; Thomas L Sutton; Stephanie M Krasnow; Christopher R Deig; Brett C Sheppard; Daniel L Marks; Aaron J Grossberg Journal: Am J Surg Date: 2022-03-26 Impact factor: 3.125
Authors: Maria Del Grande; Stefania Rizzo; Gabriele Maria Nicolino; Ilaria Colombo; Lorenzo Rossi; Lucia Manganaro; Filippo Del Grande Journal: Front Oncol Date: 2021-11-16 Impact factor: 6.244
Authors: Gabriel F P Aleixo; Shlomit S Shachar; Kirsten A Nyrop; Hyman B Muss; Claudio L Battaglini; Grant R Williams Journal: Oncologist Date: 2019-11-12 Impact factor: 5.837